Interview: Christopher Tsai, Chairman, Bionet, Taiwan
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
Organization Activities
BIONET Corp. was first established in 1999 as the pioneer company in the field of stem cell application in Taiwan as well as in Asia. BIONET has focused: “Stem Cell Therapy” and “Genetic Testing”. In 2007, BIONET completed initial public offering (TPO: 1784) and became the first publicly traded company in the stem cell and genetic industry of Taiwan. Furthermore, in 2012, Genesis Genetics Asia Corp. (GGA), a subsidiary of BIONET, made its IPO (TPO: 4160) as Taiwan’s first public company specialized in both genetic testing and scientific informatics. BIONET is the largest enterprise that the penetration rate is up to 50% for cell therapy and genetic engineering industry in Taiwan.
Contact Information
Address: No.28, 36 Ln., Xinhu 1st Rd.,
Neihu Dist., Taipei City 11494
Taiwan
Phone: +886-2-2795-1777, Monday to Friday, 9am-6pm CST (UTC+8)
Toll-free: 0800-800-018
Email: service@babybanks.com
Website: www.babybanks.com
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
The managing director of Burrill & Company discusses the biotech industry in Taiwan, the various hurdles the market faces and why there is so much potential for industry growth in…
TaiGen is on the brink of releasing Taiwan’s first innovative drug. In this interview, the Chairman and CEO of the company discusses the development path the company chose to take,…
An expert perspective on the possibilities of self-pay markets in Taiwan, and the opportunities afforded by bringing manufacturing of medical technology to the country, for export to the region. Uni-Pharma…
You have been in Taiwan now for ten months. What are the most important characteristics of this market from your perspective, and what surprised you most about Taiwan? Taiwan is…
A round-table discussion with leading figures from Taiwan’s NHRI, covering perspectives on the current state of the Taiwanese healthcare and pharmaceutical environment, links between academia and industry, the potential of…
In the first part of this two-part interview, the Chairman of TTY Biopharm considers the success of his long-term strategy to streamline TTY’s portfolio and focus on the company’s strengths,…
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
The President of Gene Health, a company specialized in genomics testing, talks about the current market situation for genomic testing, and building the business in the Chinese market, as well…
The Director General of one of the world’s most successful science parks discusses the history of the park, the reasons behind its incredible success, the unique set-up of the park…
The General Director of the ‘Invest in Taiwan’ program discusses Taiwan’s competitiveness on a global and regional level, highlights the areas and industrial sectors where the country is looking to…
In the first of this two-part interview, the chairperson of UBI and UBI Asia explains the work that her company has done to improve the landscape for Taiwanese pharma and…
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
See our Cookie Privacy Policy Here
